During observation, patients with abnormal decrease in left ventricle ejection fraction (LVEF) >10% had significantly elevated levels of MPO and TM both at baseline and after the first dose of chemotherapy based on doxorubicine compared to patients with normal LVEF after adjustment for race, age, BMI, and biological subtype of breast cancer [9]. This evidence concerns the gene MPO and breast carcinoma.